• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动力学因素控制着人类免疫缺陷病毒的细胞进入效率、进入抑制剂的效力以及适应机制。

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

作者信息

Platt Emily J, Durnin James P, Kabat David

机构信息

Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239-3098, USA.

出版信息

J Virol. 2005 Apr;79(7):4347-56. doi: 10.1128/JVI.79.7.4347-4356.2005.

DOI:10.1128/JVI.79.7.4347-4356.2005
PMID:15767435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1061535/
Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) in diverse conditions limiting for viral entry into cells frequently leads to adaptive mutations in the V3 loop of the gp120 envelope glycoprotein. This has suggested that the V3 loop limits the efficiencies of HIV-1 infections, possibly by directly affecting gp120-coreceptor affinities. In contrast, V3 loop mutations that enable HIV-1(JR-CSF) to use the low-affinity mutant coreceptor CCR5(Y14N) are shown here to have negligible effects on the virus-coreceptor affinity but to dramatically accelerate the irreversible conformational conversion of the envelope gp41 subunits from a three-stranded coil into a six-helix bundle. This slow step is blocked irreversibly by the inhibitor T-20. To further evaluate the role of entry rates in controlling infection efficiencies and viral adaptations, we developed methods to quantitatively measure viral entry kinetics. The virions were adsorbed by spinoculation at 4 degrees C onto HeLa-CD4/CCR5 cell clones that either had limiting or saturating concentrations of CCR5. After warming to 37 degrees C, the completion of entry was monitored over time by the resistance of infections to the competitive CCR5 inhibitor TAK-779. Our results suggest that the efficiency of entry of cell-attached infectious HIV-1 is principally controlled by three kinetic processes. The first is a lag phase that is caused in part by the concentration-dependent reversible association of virus with CD4 and CCR5 to form an equilibrium assemblage of complexes. Second, this assembly step lowers but does not eliminate a large activation energy barrier for a rate-limiting, CCR5-dependent conformational change in gp41 that is sensitive to blockage by T-20. The rate of infection therefore depends on the fraction of infectious virions that are sufficiently saturated with CCR5 to undergo this conformational change and on the magnitude of the activation energy barrier. Although only a small fraction of fully assembled viral complexes overcome this barrier per hour, the ensuing steps of entry are rapidly completed within 5 to 10 min. Thus, this barrier limits the overall flow rate at which the attached virions enter cells, but it has no effect on the lag time that precedes this entry flow. Third, a relatively rapid and kinetically dominant process of viral inactivation, which may partly involve endocytosis, competes with infectious viral entry. Our results suggest that the V3 loop of gp120 has a major effect on the rate-limiting coreceptor-dependent conformational change in gp41 and that adaptive viral mutations, including V3 loop mutations, function kinetically by accelerating this inherently slow step in the entry pathway.

摘要

在多种限制病毒进入细胞的条件下,人类免疫缺陷病毒1型(HIV-1)的复制常常导致包膜糖蛋白gp120的V3环发生适应性突变。这表明V3环可能通过直接影响gp120与共受体的亲和力来限制HIV-1感染的效率。相比之下,本文显示能使HIV-1(JR-CSF)利用低亲和力突变共受体CCR5(Y14N)的V3环突变对病毒与共受体的亲和力影响可忽略不计,但能显著加速包膜糖蛋白gp41亚基从三链螺旋不可逆地转变为六螺旋束。这一缓慢步骤会被抑制剂T-20不可逆地阻断。为了进一步评估进入速率在控制感染效率和病毒适应性方面的作用,我们开发了定量测量病毒进入动力学的方法。病毒粒子在4℃下通过离心接种吸附到CCR5浓度有限或饱和的HeLa-CD4/CCR5细胞克隆上。升温至37℃后,通过感染对竞争性CCR5抑制剂TAK-779的抗性随时间监测进入的完成情况。我们的结果表明,细胞附着的感染性HIV-1的进入效率主要由三个动力学过程控制。第一个是延迟期,部分原因是病毒与CD4和CCR5的浓度依赖性可逆结合,形成复合物的平衡组合。其次,这个组装步骤降低了但并未消除gp41中依赖CCR5的限速构象变化的大活化能障碍,该变化对T-20的阻断敏感。因此感染速率取决于被CCR5充分饱和以经历这种构象变化的感染性病毒粒子的比例以及活化能障碍的大小。尽管每小时只有一小部分完全组装的病毒复合物能克服这个障碍,但随后的进入步骤会在5到10分钟内迅速完成。因此,这个障碍限制了附着病毒粒子进入细胞的总体流速,但对进入流之前的延迟时间没有影响。第三,一个相对快速且在动力学上占主导的病毒失活过程(可能部分涉及内吞作用)与感染性病毒进入相互竞争。我们的结果表明,gp120的V3环对gp41中依赖共受体的限速构象变化有主要影响,并且包括V3环突变在内的适应性病毒突变通过加速进入途径中这个固有的缓慢步骤在动力学上发挥作用。

相似文献

1
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.动力学因素控制着人类免疫缺陷病毒的细胞进入效率、进入抑制剂的效力以及适应机制。
J Virol. 2005 Apr;79(7):4347-56. doi: 10.1128/JVI.79.7.4347-4356.2005.
2
Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.能够有效利用缺乏酪氨酸硫酸化氨基末端的CCR5的1型人类免疫缺陷病毒变体在gp120中存在适应性突变,包括功能性N-聚糖的缺失。
J Virol. 2005 Apr;79(7):4357-68. doi: 10.1128/JVI.79.7.4357-4368.2005.
3
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.人类免疫缺陷病毒1型(HIV-1)对进入抑制剂的敏感性与包膜/共受体亲和力、受体密度及融合动力学相关。
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. doi: 10.1073/pnas.252469399. Epub 2002 Nov 20.
4
Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.gp120 V3 环中的适应性突变增强了人类免疫缺陷病毒 1 型的融合能力,并使其能够利用缺乏氨基末端硫酸化区域的 CCR5 共受体。
J Virol. 2001 Dec;75(24):12266-78. doi: 10.1128/JVI.75.24.12266-12278.2001.
5
Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.酪氨酸硫酸化肽可逆且高效地激活 HIV-1 细胞进入,揭示了内吞进入和抑制剂作用机制。
J Virol. 2014 Apr;88(8):4304-18. doi: 10.1128/JVI.03447-13. Epub 2014 Jan 29.
6
Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.突变增加了 HIV-1 包膜糖蛋白 gp41 的融合后构象稳定性,被 X4 和 R5 HIV-1 病毒选择以逃避针对 gp41 七肽重复 1 的融合抑制剂,但两种病毒的 gp120 适应性突变不同。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.00142-19. Print 2019 Jun 1.
7
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.共受体结合位点突变对1型人类免疫缺陷病毒融合、感染及进入抑制剂敏感性的影响
J Virol. 2004 May;78(10):5476-85. doi: 10.1128/jvi.78.10.5476-5485.2004.
8
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.CD4模拟化合物对原代人免疫缺陷病毒包膜糖蛋白三聚体的激活与失活作用
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01880-16. Print 2017 Feb 1.
9
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.1型人类免疫缺陷病毒对融合抑制剂T-20的敏感性受gp120 V3环所定义的共受体特异性调节。
J Virol. 2000 Sep;74(18):8358-67. doi: 10.1128/jvi.74.18.8358-8367.2000.
10
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.人类免疫缺陷病毒1型V3区冠部的自然变异会影响复制适应性和对进入抑制剂的敏感性。
J Virol. 2007 Aug;81(15):8258-69. doi: 10.1128/JVI.02739-06. Epub 2007 May 23.

引用本文的文献

1
Transmitted/founder (T/F) HIV-1 derived from sexual contact exhibits greater transmission fitness in human cervical tissue than T/F HIV-1 from blood-to-blood contact: Unique glycan profiles on T/F envelopes associated with transmission phenotypes.通过性接触传播的/奠基者(T/F)HIV-1在人宫颈组织中的传播适应性高于通过血液接触传播的T/F HIV-1:T/F包膜上与传播表型相关的独特聚糖谱。
PLoS Pathog. 2025 May 23;21(5):e1013177. doi: 10.1371/journal.ppat.1013177. eCollection 2025 May.
2
A Systematic Review Exploring the Range of Renal Complications of Human Immunodeficiency Virus.一项探索人类免疫缺陷病毒肾脏并发症范围的系统评价
Cureus. 2023 Mar 27;15(3):e36755. doi: 10.7759/cureus.36755. eCollection 2023 Mar.
3
Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.通过 HIV-1 包膜蛋白Env 顶点的相互作用调节 gp41 膜近端外部区的表位暴露。
PLoS Pathog. 2022 May 18;18(5):e1010531. doi: 10.1371/journal.ppat.1010531. eCollection 2022 May.
4
Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies.鉴定允许 HIV-1 进入和产生感染的 CCR5 核心受体群体:对体内研究的意义。
J Transl Med. 2022 Jan 24;20(1):39. doi: 10.1186/s12967-022-03243-8.
5
Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.鉴定和表征一种小分子狂犬病病毒进入抑制剂。
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00321-20.
6
HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.HIV-1 锚定抑制剂和膜融合抑制剂针对病毒进入的不同但重叠的步骤。
J Biol Chem. 2019 Apr 12;294(15):5736-5746. doi: 10.1074/jbc.RA119.007360. Epub 2019 Jan 29.
7
The Effects of Statistical Multiplicity of Infection on Virus Quantification and Infectivity Assays.统计多重感染对病毒定量和感染性测定的影响。
Biophys J. 2018 Jun 19;114(12):2974-2985. doi: 10.1016/j.bpj.2018.05.005.
8
Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion.HIV-1 gp41 的膜近端胞外结构域 (MPER) 在游离细胞和细胞间病毒传播以及细胞间融合中的不同功能。
J Biol Chem. 2018 Apr 20;293(16):6099-6120. doi: 10.1074/jbc.RA117.000537. Epub 2018 Mar 1.
9
Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine.HIV-1 进入的融合阶段取决于病毒诱导的磷脂酰丝氨酸在细胞表面的暴露。
Cell Host Microbe. 2017 Jul 12;22(1):99-110.e7. doi: 10.1016/j.chom.2017.06.012.
10
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.动力学因素的复杂相互作用决定了HIV-1进入抑制剂的协同特性。
J Biol Chem. 2017 Oct 6;292(40):16498-16510. doi: 10.1074/jbc.M117.791731. Epub 2017 Jul 10.

本文引用的文献

1
Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.能够有效利用缺乏酪氨酸硫酸化氨基末端的CCR5的1型人类免疫缺陷病毒变体在gp120中存在适应性突变,包括功能性N-聚糖的缺失。
J Virol. 2005 Apr;79(7):4357-68. doi: 10.1128/JVI.79.7.4357-4368.2005.
2
HIV-1 entry inhibitor entrances.HIV-1进入抑制剂入口。
Trends Pharmacol Sci. 2004 Mar;25(3):117-20. doi: 10.1016/j.tips.2004.01.005.
3
The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.人类免疫缺陷病毒1型在原代淋巴细胞中的长期培养会增加其对可溶性CD4中和作用的敏感性。
Virology. 2004 Mar 30;321(1):8-22. doi: 10.1016/j.virol.2003.12.012.
4
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.gp120包膜糖蛋白的局部变化赋予对人类免疫缺陷病毒进入抑制剂BMS - 806和#155的抗性。
J Virol. 2004 Apr;78(7):3742-52. doi: 10.1128/jvi.78.7.3742-3752.2004.
5
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.1型人类免疫缺陷病毒对小分子CCR5抑制剂逃逸的遗传与表型分析
J Virol. 2004 Mar;78(6):2790-807. doi: 10.1128/jvi.78.6.2790-2807.2004.
6
Fluorescence resonance energy transfer-based HIV-1 virion fusion assay.基于荧光共振能量转移的HIV-1病毒体融合检测法。
Methods Mol Biol. 2004;263:333-44. doi: 10.1385/1-59259-773-4:333.
7
Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.人类CD4 T淋巴细胞中1型人类免疫缺陷病毒融合与胞吞作用之间的代偿性联系
J Virol. 2004 Feb;78(3):1375-83. doi: 10.1128/jvi.78.3.1375-1383.2004.
8
Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions.4-苯甲酰基-1-[(4-甲氧基-1H-吡咯并[2,3-b]吡啶-3-基)氧代乙酰基]-2-(R)-甲基哌嗪(BMS-378806)的发现:一种新型的HIV-1附着抑制剂,可干扰CD4与gp120的相互作用。
J Med Chem. 2003 Sep 25;46(20):4236-9. doi: 10.1021/jm034082o.
9
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.一种靶向HIV-1包膜并抑制CD4受体结合的小分子HIV-1抑制剂。
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11013-8. doi: 10.1073/pnas.1832214100. Epub 2003 Aug 20.
10
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.HIV-1包膜蛋白在融合孔形成后立即完成折叠形成六螺旋束。
Mol Biol Cell. 2003 Mar;14(3):926-38. doi: 10.1091/mbc.e02-09-0573.